Stock IPOs
Iambic attracts Wall Street attention; clinical proof remains the test
IAM’s supplied chart shows $15.30 and +14.35%. Analyst coverage adds attention, but AI-drug discovery still has to deliver clinical evidence.
Read the story
Stock IPOsRecent IPO Gainers: The News Behind CSQR, IAM and MWC
Csquare, Iambic and Micware feature in a supplied gainers screen. November 9–10 earnings and analyst coverage offer context, with important caveats.
PEPG Jumps About 114% in Snapshot as New DM1 Trial Results Arrive
PepGen’s sharp snapshot gain accompanies new DM1 trial data. Small patient numbers, an active U.S. clinical hold and future funding remain important.
CODX Shows a 74.45% Gain in After-Hours Snapshot Ahead of Earnings
The latest supplied CODX snapshot shows $0.45 and a 74.45% gain. India tuberculosis plans, November 10 earnings and convertible financing frame the business story.
HRTX Jumps About 31% in Snapshot as CorMedix Asset Deal Reshapes Heron’s Future
Heron’s proposed asset sale brings cash and CorMedix shares, but closing conditions, debt and its next business strategy remain central for HRTX holders.
EDSA Jumps 34% on Kyorin Deal: $12 Million Upfront, Bigger Tests Ahead
EDSA's 34% snapshot rally follows a Kyorin licensing deal. Examine the $12 million upfront payment, conditional milestones, clinical evidence and chart risks.
ANVS Falls Nearly 48% as $21 Million Offering Puts Dilution in Focus
Annovis Bio's share-and-warrant offering raises funding while adding ownership pressure, against the backdrop of a recent NYSE compliance notice.